Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Low-Dose Fractionated Radiotherapy as a Chemosensitizer for Gemcitabine and Erlotinib in Patients With Locally Advanced or Limited Metastatic Pancreatic Cancer

NCT00761345 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT00761345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00761345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Low-Dose Fractionated Radiotherapy as a Chemosensitizer for Gemcitabine and Erlotinib in Patients With Locally Advanced or Limited Metastatic Pancreatic Cancer
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2008
Completion date
February 28, 2015
Enrollment
27 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer, pancreatic carcinoma non-resectable